Kathleen Haskell
Impact in
- Molecular Biology top 10%
- PI3K/AKT/mTOR signaling in cancer
- Protein Kinase Regulation and GTPase Signaling
- Epigenetics and DNA Methylation
- Ubiquitin and proteasome pathways
- Oncology top 10%
- Cancer-related Molecular Pathways
Papers in
- Co-authors
- Deborah Defeo-JonesRaymond E. JonesHans E. HuberKaren LeanderGerald A. VuocoloElizabeth McAvoyR. RobinsonA Oliff
- Journals
- Biochemical Journal (2 papers)Molecular Therapy (1 paper)iScience (1 paper)Nature Medicine (1 paper)Molecular Cancer Therapeutics (1 paper)
- Partner nations
- United StatesIrelandCanada
In The Last Decade
Kathleen Haskell
17 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 83
- Molecular Biology 884
- Oncology 351
- Cancer Research 116
- Genetics 71
- Ophthalmology 53
Countries citing papers authored by Kathleen Haskell
This map shows the geographic impact of Kathleen Haskell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathleen Haskell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathleen Haskell more than expected).
Fields of papers citing papers by Kathleen Haskell
This network shows the impact of papers produced by Kathleen Haskell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathleen Haskell. The network helps show where Kathleen Haskell may publish in the future.
Co-authors
The 25 scholars most cited alongside Kathleen Haskell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2021 | 33 | |
| 3 | 2021 | 3 | |
| 4 | 2012 | 4 | |
| 5 | 2010 | 53 | |
| 6 | Abstract #3714: In vitro and in vivo antitumor activities of MK-2206, a new allosteric Akt inhibitor | 2009 | 11 |
| 7 | 2008 | 56 | |
| 8 | 2005 | 326 | |
| 9 | 2005 | 148 | |
| 10 | A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivo. | 2002 | 33 |
| 11 | 2000 | 127 | |
| 12 | 1993 | 15 | |
| 13 | 1993 | 53 | |
| 14 | 1991 | 9 | |
| 15 | 1991 | 297 | |
| 16 | Mammalian cell lines engineered to identify inhibitors of specific signal transduction pathways. | 1991 | 12 |
| 17 | 1989 | 8 | |
| 18 | 1989 | 50 |
About Kathleen Haskell
Kathleen Haskell is a scholar working on Behavioral Neuroscience, Biophysics, Molecular Biology, Endocrinology, Diabetes and Metabolism and Ophthalmology, having authored 18 papers that have together received 1.2k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (5 papers), Quinazolinone synthesis and applications (3 papers), Virus-based gene therapy research (2 papers), Cervical Cancer and HPV Research (2 papers), RNA Interference and Gene Delivery (2 papers), Biochemical and Molecular Research (2 papers), Advanced biosensing and bioanalysis techniques (2 papers) and Herpesvirus Infections and Treatments (2 papers). The work is most often cited by research in Molecular Biology (884 citations), Oncology (351 citations), Cancer Research (116 citations), Genetics (71 citations) and Ophthalmology (53 citations). Kathleen Haskell has collaborated with scholars based in United States, Ireland and Canada. Frequent co-authors include Deborah Defeo-Jones, Raymond E. Jones, Hans E. Huber, Karen Leander, Gerald A. Vuocolo, Elizabeth McAvoy, R. Robinson, A Oliff, Stanley F. Barnett and Pearl S. Huang. Their work appears in journals such as Biochemical Journal, Molecular Therapy, iScience, Nature Medicine and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.